The short answer
Added low blood pressure from CoQ10 with lofexidine has not been established. Lofexidine itself can cause dizziness, low blood pressure and a slow pulse, so include CoQ10 in your treatment team’s supplement review.
What this answer covers
Oral Coenzyme Q10 products during prescribed oral lofexidine treatment; no assumed equivalence of every formulation.
- Supplement or preparation
- Coenzyme Q10
- Medication ingredient
- lofexidine
What the CoQ10 trial found
In a controlled study of patients already taking blood-pressure medicines, CoQ10 did not significantly lower the primary average 24-hour blood-pressure measurements. Some secondary measurements changed, but that does not establish a low-pressure interaction with lofexidine.
Why lofexidine still needs monitoring
Lofexidine can lower blood pressure and pulse during treatment for opioid withdrawal. A large controlled trial also reported these effects. They can occur without CoQ10.
Review the actual supplement
Tell the treatment team the product, dose and reason for use. The evidence does not establish a special CoQ10 dose or spacing interval during lofexidine treatment.
What to do if you become lightheaded
If you feel dizzy or faint, sit or lie down. The lofexidine label tells outpatients with symptoms of low blood pressure or a slow pulse to withhold a dose and contact the prescriber for guidance. Follow your treatment team’s monitoring plan; do not make a permanent abrupt stop on your own.
Evidence and practical considerations
Side effects & toxicity
The exact-pair hypotension claim is unproven; current CoQ10 evidence does not establish a meaningful average pressure-lowering effect.
- Exact scope
- Oral Coenzyme Q10 products during prescribed oral lofexidine treatment; no assumed equivalence of every formulation. with Oral lofexidine for adult opioid withdrawal; label section 11 supports hydrochloride-to-active-moiety identity.
- Medication form and route
- oral supplement unless clinician-directed electrolyte correction requires another route
- Timing or duration
- Lofexidine course is symptom-guided up to 14 days; longer supplement studies do not establish acute co-use safety.
What remains uncertain
- No lofexidine co-use trial. CoQ10 secondary endpoint changes do not establish symptomatic hypotension.
Factors that may matter: exact preparation; blood pressure and pulse; kidney function; other medicines; baseline electrolyte status or alertness.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Adults receiving treatment for opioid withdrawal symptoms.
Can cause hypotension, bradycardia, syncope and sedation. Avoid medicines lowering pulse or pressure; potentiates benzodiazepine CNS depression and is expected to potentiate other sedating drugs. Correct hypokalemia/hypomagnesemia first and monitor ECG at initiation in those patients because lofexidine prolongs QT. Abrupt discontinuation can raise blood pressure.
How this applies: RxNorm 28863 IN maps to this SPL; section 11 confirms salt-to-active-moiety identity. Applies to prescribed oral lofexidine for adult opioid withdrawal, not another alpha-2 agonist.
Does not establish supplement depletion, automatic supplementation, exact botanical interaction rates or a safe supplement spacing interval.
Source 2: original controlled human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 30 patients with metabolic syndrome and hypertension on unchanged conventional therapy.
No significant reduction in primary 24-hour systolic or diastolic pressure or heart rate. Some secondary daytime diastolic load measures improved.
How this applies: Exact preparation and population context; does not measure this supplement with lofexidine.
No lofexidine or opioid withdrawal. Null average effect cannot exclude an individual response; primary and secondary outcomes differ.
Source 3: official guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: CoQ10 supplement users.
Limited available evidence suggests no meaningful effect on blood pressure.
How this applies: Challenges treating CoQ10 as an established blood-pressure-lowering drug.
General assessment, not an exact lofexidine study.
Source 4: original controlled human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 603 adults seeking withdrawal from short-acting opioids.
Reduced withdrawal symptoms and improved completion rates; common adverse effects included orthostatic hypotension, hypotension and bradycardia.
How this applies: Exact preparation and population context; does not measure this supplement with lofexidine.
No requested supplement co-use analysis; overall similar adverse-event rates do not eliminate specific cardiovascular effects.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Inspected sources applied to exact current available claim; no clinical review asserted. | |
| Research summary published |
Article revision: ce3673278962add2
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.